Clinical Trials
3
Active:2
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)TIP in Patients Affected by Metastatic TNBC
Recruiting
- Conditions
- Metastatic Triple-negative Breast Cancer
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Fondazione per la Medicina Personalizzata
- Target Recruit Count
- 100
- Registration Number
- NCT05831553
- Locations
- 🇮🇹
Ospedale Santo Stefano, Prato, FI, Italy
🇮🇹IRCCS Istituto Europeo di Oncologia IEO, Milano, MI, Italy
🇮🇹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, RM, Italy
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
Phase 2
Active, not recruiting
- Conditions
- Other CancerBreast CancerGastrointestinal CancerNon Small Cell Lung Cancer
- Interventions
- Drug: Oncology DrugsDrug: Vismogedib
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Fondazione per la Medicina Personalizzata
- Target Recruit Count
- 400
- Registration Number
- NCT04591431
- Locations
- 🇮🇹
OSPEDALI RIUNITI di ANCONA, Ancona, Italy
🇮🇹Centro Riferimento Oncologico, Aviano, Italy
🇮🇹Irccs Oncologico Istituto Tumori Giovanni Paolo Ii - Bari, Bari, Italy
News
No news found